Commentary
Volume 08:05, 2025

Journal of Brain Research

ISSN: 2684-4583

Open Access

Brain Tumor Research: Personalized and Novel Therapies

Valentina Rossi*

Department of Neurodegenerative Diseases Mediterraneo Biomedical University Naples, Italy

Introduction

Understanding the intricate biology of brain tumors is paramount for developing effective therapeutic strategies. Recent advancements highlight the heterogeneity of glioblastoma, emphasizing the need for personalized treatments. Targeting key signaling pathways, such as the PI3K/Akt/mTOR and MAPK pathways, along with exploring immunotherapeutic approaches and novel drug delivery systems, are promising avenues in improving patient outcomes [1].

The tumor microenvironment in brain tumors plays a critical role in tumor progression and therapeutic resistance. Modulating the immune response within the brain, particularly focusing on microglia and astrocytes, offers a novel therapeutic target. Strategies aim to reprogram these cells to an anti-tumorigenic state, thereby enhancing the efficacy of conventional treatments [2].

Epigenetic alterations are increasingly recognized as drivers of brain tumor development and are also amenable to therapeutic intervention. Targeting histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) has shown promise in preclinical models, with ongoing clinical trials investigating their efficacy in various brain tumor types [3].

Liquid biopsies are emerging as a valuable tool in brain tumor management, offering a less invasive approach for diagnosis, monitoring treatment response, and detecting recurrence. Analysis of circulating tumor DNA (ctDNA) and extracellular vesicles (EVs) can provide real-time insights into tumor heterogeneity and molecular evolution [4].

The development of resistance to targeted therapies is a major hurdle in brain tumor treatment. Understanding the molecular mechanisms underlying resistance, such as acquired mutations or activation of alternative signaling pathways, is crucial for designing combination therapies and overcoming treatment failure [5].

Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. While initial responses in brain tumors have been modest, ongoing research focuses on enhancing ICI efficacy through combination strategies, such as combining with radiation therapy or novel immunomodulatory agents, and understanding the role of the blood-brain barrier in limiting T-cell infiltration [6].

Targeting tumor metabolism represents a promising therapeutic avenue. Cancer cells exhibit altered metabolic profiles to support their rapid proliferation. Inhibiting key metabolic enzymes or pathways, such as glycolysis or glutaminolysis, can starve tumor cells of essential nutrients and energy, thus hindering their growth [7].

Oncolytic viruses offer a dual therapeutic approach, directly killing tumor cells and stimulating an anti-tumor immune response. Genetically engineered oncolytic viruses are being developed to specifically target brain tumor cells while sparing healthy tissue, with ongoing investigations into their safety and efficacy in clinical trials [8].

Precision medicine approaches, guided by molecular profiling of individual brain tumors, are increasingly important. Identifying specific genetic alterations and actionable mutations allows for the selection of targeted therapies that are more likely to be effective for a given patient [9].

The blood-brain barrier (BBB) poses a significant challenge to the delivery of therapeutics to brain tumors. Novel drug delivery strategies, including nanoparticle-based systems, focused ultrasound, and convection-enhanced delivery, are being investigated to overcome the BBB and improve drug penetration into the tumor core [10].

Description

The intricate biology of brain tumors necessitates a deep understanding for the development of effective therapeutic strategies. Glioblastoma, in particular, is characterized by its heterogeneity, underscoring the need for personalized treatment approaches. Promising avenues for improving patient outcomes involve targeting key signaling pathways like PI3K/Akt/mTOR and MAPK, alongside exploring immunotherapeutic interventions and innovative drug delivery systems [1].

The tumor microenvironment significantly influences brain tumor progression and resistance to therapy. Modulating the brain's immune response, specifically targeting microglia and astrocytes, presents a novel therapeutic strategy. The goal is to reprogram these cells into an anti-tumorigenic state, thereby augmenting the effectiveness of existing treatments [2].

Epigenetic modifications are recognized as key drivers in brain tumor development and represent a targetable aspect of therapy. Preclinical models have shown promise with interventions targeting histone deacetylases (HDACs) and DNA methyltransferases (DNMTs), and clinical trials are actively evaluating their efficacy across various brain tumor types [3].

Liquid biopsies are increasingly valuable in brain tumor management due to their minimally invasive nature. They facilitate diagnosis, monitoring of treatment response, and early detection of recurrence. Analyzing circulating tumor DNA (ctDNA) and extracellular vesicles (EVs) offers real-time insights into tumor heterogeneity and its molecular evolution [4].

Therapeutic resistance remains a significant obstacle in treating brain tumors. Comprehending the molecular mechanisms behind resistance, such as acquired mutations or the activation of alternative signaling pathways, is vital for designing effective combination therapies and overcoming treatment failures [5].

Immunotherapy, especially immune checkpoint inhibitors (ICIs), has transformed cancer care. Although initial responses in brain tumors have been modest, research is actively pursuing strategies to enhance ICI effectiveness. This includes combination therapies with radiation or novel immunomodulatory agents, and a

deeper understanding of the blood-brain barrier's impact on T-cell infiltration [6].

Targeting tumor metabolism is a promising therapeutic strategy, given that cancer cells exhibit altered metabolic profiles to fuel their rapid growth. Inhibiting critical metabolic enzymes or pathways, such as glycolysis or glutaminolysis, can deprive tumor cells of essential nutrients and energy, thereby impeding their proliferation [7].

Oncolytic viruses offer a dual mechanism of action: direct tumor cell lysis and the stimulation of an anti-tumor immune response. Genetically engineered oncolytic viruses are being developed for targeted delivery to brain tumor cells, sparing healthy tissue. Their safety and efficacy are currently under investigation in clinical trials [8].

Precision medicine, guided by the molecular profiling of individual brain tumors, is becoming increasingly crucial. Identifying specific genetic alterations and actionable mutations enables the selection of targeted therapies with a higher probability of success for individual patients [9].

The blood-brain barrier (BBB) presents a formidable challenge for delivering therapeutic agents to brain tumors. Emerging strategies to overcome the BBB and enhance drug penetration into the tumor core include nanoparticle-based systems, focused ultrasound, and convection-enhanced delivery [10].

Conclusion

Brain tumor research is advancing rapidly, focusing on personalized treatments due to tumor heterogeneity, particularly in glioblastoma. Key strategies include targeting signaling pathways, modulating the tumor microenvironment, and utilizing epigenetic therapies. Liquid biopsies offer a less invasive approach for monitoring and diagnosis. Overcoming therapeutic resistance is critical, and combination therapies are being explored. Immunotherapy, while showing promise, faces challenges like the blood-brain barrier. Metabolic reprogramming and oncolytic viruses are novel therapeutic avenues. Precision medicine, guided by molecular profiling, is essential for selecting effective targeted therapies. Novel drug delivery systems are being developed to overcome the blood-brain barrier, improving drug penetration into tumors.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ghosal, Koushik, Sinha, Suman Kumar, Bhattacharyya, Anirban. "Glioblastoma Biology and Therapeutic Strategies: A Comprehensive Review." *J Neurooncol* 152 (2021):115-135.
2. Wen, Yan, Xie, Wen, Su, Yanying. "The Tumor Microenvironment in Glioblastoma: A Target for Novel Therapies." *Front Immunol* 11 (2020):1886.
3. Cheng, Yuan, Liu, Shiqi, Wang, Xiaoting. "Epigenetic Therapies in Brain Tumors: A Focus on HDAC and DNMT Inhibitors." *Cancer Lett* 461 (2019):203-211.
4. Tzschach, Andreas, Weller, Michael, Strobel, Christine. "Liquid Biopsies for Brain Tumors: Progress and Challenges." *Nat Rev Clin Oncol* 20 (2023):512-527.
5. Kim, Ji-Eun, Lee, Hyun-Young, Park, Chang-Jin. "Mechanisms of Resistance to Targeted Therapy in Brain Tumors." *Mol Cancer Ther* 21 (2022):1115-1127.
6. Reardon, D. Louis, Brandes, Alberto, Dirks, Paul. "The Blood-Brain Barrier: A Hurdle for Immunotherapy in Brain Tumors." *J Immunother Cancer* 8 (2020):e000614.
7. Sonveaux, Philippe, Galartis, Angela, Eggermont, Alexander M. M.. "Metabolic Reprogramming in Brain Tumors: Therapeutic Implications." *Front Oncol* 11 (2021):708187.
8. Liu, Bing, Li, Wenjie, Guo, Zhiqiang. "Oncolytic Viruses for Brain Tumor Therapy: Current Status and Future Prospects." *Mol Ther* 30 (2022):2255-2266.
9. Chauhan, Deepa, Sarkar, Chandrima, Bhat, Kshitij. "Precision Medicine in Glioblastoma: Current Landscape and Future Directions." *Neuro Oncol* 23 (2021):1369-1382.
10. Xing, Yuan, Sun, Hongjian, Guo, Xiangyu. "Overcoming the Blood-Brain Barrier for Effective Brain Tumor Therapy." *Adv Drug Deliv Rev* 198 (2023):114027.

How to cite this article: Rossi, Valentina. "Brain Tumor Research: Personalized and Novel Therapies." *J Brain Res* 08 (2025):335.

Address for Correspondence: Valentina, Rossi, Department of Neurodegenerative Diseases Mediterraneo Biomedical University Naples, Italy, E-mail: v.rossi@med.it

Received: 02-Oct-2025, Manuscript No. jbr-26-182907; **Editor assigned:** 06-Oct-2025, PreQC No. P-182907; **Reviewed:** 20-Oct-2025, QC No. Q-182907; **Revised:** 23-Oct-2025, Manuscript No. R-182907; **Published:** 30-Oct-2025, DOI: 10.38421/2684-4583.2025.8.335